Melanoma (MEL) Research Program

项目概要/摘要： 黑色素瘤项目（MEL）开展了有影响力的研究，旨在通过以下措施改善患者的预后： 了解黑色素瘤生物学和解决黑色素瘤管理中未满足的需求。这一努力是 由全国最古老和最大的黑色素瘤标本生物库之一提供便利，与前瞻性， 以及3,700多名患者的方案驱动的临床信息。特别关注的领域包括： 初步治疗后复发风险分层，改善辅助治疗的决策， 那些复发风险高的人，确定黑色素瘤进展的分子驱动因素， 特别关注大脑向性，并为晚期黑色素瘤患者开发新的治疗方法。领导 医学博士Iman Osman和医学博士Jeffrey Weber MEL由21名成员组成的多学科团队组成 代表纽约大学医学院和其他纽约大学学院的12个系， 科学、转化和临床黑色素瘤研究。六个新成员满足了战略需求， 推进了我们将新疗法引入临床的目标。MEL还大大增强了其 针对PCC集水区的研究和推广，对肢端黑色素瘤进行新的努力， 非裔美国人和西班牙裔美国人也会患糖尿病。自上次CCSG审查以来，我们的NCI资金已经 从72.9万美元增加到210万美元，几乎增加了两倍，而与癌症相关的资金总额从340万美元增加到210万美元，几乎翻了一番。 六百零三万会员发表了354篇论文，其中31%的引文出现在IF>10的期刊上。 成员之间高度协作：19%的出版物是方案内的，31%的出版物是方案内的， 35%是机构间的（与国家信息通报中心合作）。在这段时间里， 在理解黑色素瘤细胞起源和转移机制方面取得了重大进展， 进展我们把注意力集中在下游表观遗传和转录程序上， 其是直接“可用药的”（即，BRD 4）;间接导致新靶点出现的其他靶点（例如， HSF 1、AMIGO 2、FUT 8、PTK 7）。MEL联合领导人及其几位高级成员最近提交了一份 SPORE申请获得了很高的影响力分数，将于2018年5月重新提交。我们的科学 目标围绕三个互补的主题目标组织：目标1：确定新的预后和 黑色素瘤进展和治疗反应的预测性分子生物标志物，目的2：了解 黑色素瘤在分子水平上的生物异质性，目标3：开发新的治疗方法， 克服治疗阻力。MEL促进PCC的使命，以改善癌症治疗，结果， 通过以下方式提高患者的生活质量：（1）使患者接受高质量的、由药物启动的试验，（2） 扩大与临床信息相关的大型黑色素瘤生物库，（3）追求科学， 分层进行个性化治疗，以及（4）开发新的检测方法，早期干预 治疗晚期疾病。

Project Summary/Abstract: The Melanoma Program (MEL) carries out impactful research aimed at improving patient outcomes by understanding melanoma biology and addressing unmet needs in melanoma management. This effort is facilitated by one of the nation’s oldest and largest biobanks of melanoma specimens, linked to prospective, and protocol-driven clinical information for more than 3,700 patients. Special areas of interest include: better stratification of recurrence risk after primary treatment, improved decision making for adjuvant treatment of those at high risk of recurrence, identification of the molecular drivers of melanoma progression with a particular focus on brain tropism, and developing new therapies for patients with advanced melanoma. Led by Iman Osman, MD and Jeffrey Weber, MD PhD, MEL comprises a multi-disciplinary team of 21 members representing 12 departments at NYU School of Medicine and other NYU colleges that advances basic science, translational and clinical melanoma research. Six new members filled strategic needs, and have advanced our goal of bringing novel therapeutics into the clinic. MEL has also significantly enhanced its research and outreach targeting the PCC catchment area with a new effort on acral melanoma, which disportionately affects African Americans and Hispanics. Since the last CCSG review, our NCI funding has nearly tripled from $729K to $2.1 million, while overall cancer-related funding has almost doubled from $3.4 to $6.03 million. Members published 354 papers, with 31% of the citations appearing in journals with IF>10. Members are highly collaborative: 19% of publications are intra-programmatic, 31% of publications are intra- programmatic, and 35% are inter-institutional (with NCI-CCs). During this funding period, MEL members made major strides in understanding the melanoma cell-of-origin and the mechanisms driving metastatic progression. We have focused our attention on downstream epigenetic and transcriptional programs, some that are directly ‘druggable’ (i.e., BRD4); others that indirectly result in emergence of novel targets (e.g., HSF1, AMIGO2, FUT8, PTK7). MEL co-leaders and several of its senior members recently submitted a SPORE application, which received a high impact score and will be resubmitted in May 2018. Our scientific goals are organized around three complementary thematic aims: Aim 1: To identify novel prognostic and predictive molecular biomarker(s) of melanoma progression and response to therapy, Aim 2: To understand the biologic heterogeneity of melanoma at the molecular level, and Aim 3: To develop new treatments that overcome therapeutic resistance. MEL promotes the PCC mission to improve cancer treatment, outcome, and quality of life for patients by: (1) accruing patients to high quality, investigator-initiated trials, (2) expanding a large melanoma biobank tied to clinical information, (3) pursuing science that informs patient stratification for personalized treatment, and (4) developing new approaches to detection, early intervention and treatment of advanced disease.